Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Clinical trial NCT03684863 · UNKNOWN
Trial details
- NCT number
- NCT03684863
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-01
- Primary completion
- 2023-12-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.